期刊文献+

硼替佐米联合化疗治疗皮下脂膜炎样T细胞淋巴瘤二例报告附文献复习 被引量:3

原文传递
导出
摘要 皮下脂膜炎样T细胞淋巴瘤(subcutaneous panniculitislike T cell lymphoma,SPTCL)是一种少见的主要累及皮下脂肪组织且与脂膜炎相似的原发性皮肤淋巴瘤。其发病率低,预后差,目前治疗以联合化疗为主。现将我科使用硼替佐米联合化疗治疗2例SPTCL患者报道如下。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2008年第10期695-696,共2页 Chinese Journal of Hematology
  • 相关文献

参考文献6

  • 1Go RS, Wester SM. Immunophenotypic and molecular features, clinical outcomes, treatments, and prognostic factors associated with subcutaneous panniculitis-like T-cell lymphoma. Cancer, 2004,101 : 1404-1413.
  • 2Weenig RH, Ng CS, Pemiciaro C. Subcutaneous panniculitis-like T-cell lymphoma: an elusive case presenting as lipomembranous panniculitis and a review of 72 cases in the literature. Am J Dermatopathol, 2001,23:206-215.
  • 3穆海玉,冯义伶,郑爱青.侵犯多器官的皮下脂膜炎样T细胞淋巴瘤1例并文献复习[J].中国实用内科杂志,2007,27(9):703-705. 被引量:3
  • 4Aghajanian C, Soignet S, Dizon DS, et al. A phase Ⅰ trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res, 2002,8:2505-2511.
  • 5Goy A, Younes A, McLaughlin P, et al. Phase Ⅱ study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non- Hodgkin' s lymphoma. J Clin Oncol, 2005,23:667-675.
  • 6Mai W, Meng H, Jin J, et al. Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol, 2006,77:445-447.

二级参考文献9

共引文献2

同被引文献27

  • 1黄慧强,彭玉龙,林旭滨,孙晓菲,林桐榆,夏忠军,李宇红,蔡清清,何友兼,姜文奇,管忠震.CHOP方案治疗106例外周T细胞淋巴瘤的临床长期随访结果分析[J].癌症,2004,23(z1):1443-1447. 被引量:25
  • 2扶云碧,孙启鑫,孟凡义,谢军,周光飚.蛋白酶体抑制剂硼替佐米诱导髓系白血病细胞株 HL60凋亡的机制研究[J].中华医学杂志,2006,86(34):2413-2416. 被引量:14
  • 3王琳,万川,廖殿英,张文燕,徐晨,邱瑞成,刘卫平,李甘地.皮下脂膜炎样T细胞淋巴瘤20例临床病理分析[J].临床皮肤科杂志,2007,36(6):348-351. 被引量:15
  • 4Hideshima T,Mitsiades C,Akiyama M,et al.Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor Ps341.Blood,2003,101:1530-1534.
  • 5Horton TM,Gannavarapu A,Blaney SM,et al.Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.Cancer Chemother Pharmacol,2006,58:13-23.
  • 6Daj Y,Rahmanj M,Pei XY,et al.Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and independent mechanisms.Blood,2004,104:509-518.
  • 7Rao RV,Ellerby HM,Bredesen DE.Coupling endoplasmic reticulum stress to the cell death program.Cell Death Differ,2004,11:372-380.
  • 8Ferri KF,Kroemer G.Organelle-specific initiation of cell death pathways.Nat Cell Biol,2001,31:E255-263.
  • 9Gozzetti A,Defina M,Bocchia M,et al.Safety and efficacy of bortezomib,melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.Leuk Res,2010,34:e288 -289.
  • 10Seki N,Toh U,Sayers TJ,et al.Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.Mol Cancer Ther,2010,9:1842-1851.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部